Clinical trials: Blood Plasma Therapy
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
- Trial name
- NCT05587972
- Testing
- survey
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Carevive Systems, Inc.
Osteonecrosis Due to Drugs, Jaw
Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw
Medication related Osteonecrosis of the Jaw (MRONJ) consists of progressive destruction of bone in the maxillofacial area. It is an established complication which occurs in patients who take two main classes of antiresorptive…
- Trial name
- NCT03390777
- Testing
- surgery, PRGF after surgery
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Multiple Myeloma
Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma
Multiple myeloma is a plasma cell neoplasm that can cause painful bone lesions. The main treatment for these lesions and pain control is radiotherapy, usually in daily fractions.
- Trial name
- NCT05996367
- Testing
- Single-dose involved-site radiotherapy
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Epicondylitis
Treatment of Epicondylitis by Ultrasound-guided Local Injections of PRP (Platelet Rich Plasma)
The purpose of this study is to assess efficacy of two intra-tendinous injections of platelet-rich plasma (PRP) on epicondylitis of recent evolution (≤ 3 months) compared compared to two intra-tendinous injections of saline…
- Trial name
- NCT02378285
- Testing
- ACP, Saline solution
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Arthrex SAS
Amblyopia
Plasma Biomarker in Amblyopia Patients
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia.
- Trial name
- NCT05705778
- Testing
- standard amblyopia treatment
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Drug Interactions
Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women
Physicians might be concerned that Adempas may have a metabolic interaction with oral contraceptives (OC) that could decrease the contraceptive efficacy of the OC.
- Trial name
- NCT02159326
- Testing
- Microgynon, Riociguat (Adempas,BAY63-2521)
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
Kidney Cancer, Leukemia
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy, or that have become cancer.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00303719
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Androgenetic Alopecia
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
Platelet rich plasma (PRP) therapy is a novel therapeutic modality that has seen broad applications for a number of medical indications including those in orthopedics, dentistry, and dermatology.
- Trial name
- NCT02591355
- Testing
- Autologous Platelet Rich Plasma, Saline solution injection
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Regen Lab SA
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT00317811
- Testing
- ascorbic acid, bortezomib, melphalan
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies.
- Trial name
- NCT00257114
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carpal Tunnel
Platelet Rich Plasma Injection Versus Surgical and Medical Treatment of Mild-moderate Carpel Tunnel Syndrome.
to evaluate the therapeutic efficacy of single ultrasound guided Platelet Rich Plasma injection of the carpal tunnel Vs. surgical procedures and medical treatment and hand support in patients with mild-moderate carpal tunnel…
- Trial name
- NCT04235426
- Testing
- 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support., 30 patients went to surgical procedure, Injection
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Dalia Salah Saif
Myofascial Pain
PRGF Effectiveness for Myofascial Pain Treatment in Masticatory Muscles
The investigators set up a randomized controlled clinical trial to evaluate the effectiveness of plasma rich in growth factors (PRGF) injections into the masseter muscle trigger points for myofascial pain treatment.
- Trial name
- NCT04040309
- Testing
- PRGF injection, Lidocaine injection
- Where
- Lithuania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lithuanian University of Health Sciences
COVID 19
Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19
This research is planned to illustrate the efficacy of Therapeutic Plasma Exchange (TPE) treatment in COVID-19 patients with resistant cytokine storm state.
- Trial name
- NCT04457349
- Testing
- Therapeutic Plasma Exchange (TPE)
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Alexandria University
Osteoarthritis, Hip, Osteoarthritis
A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis
The purpose of this study is to evaluate the efficacy of one leukocyte-poor platelet-rich plasma (LP-PRP) injection to the intra-articular (IA) space in comparison to one LP-PRP injection to the IA space with an additional…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Degeneration
- Trial name
- NCT04241354
- Testing
- Leukocyte-poor platelet rich plasma
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Regenerative Orthopedics and Sports Medicine
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.
Relapsed and Refractory Multiple Myeloma
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
This clinical study is an exploratory study, mainly to study the safety and efficacy of BCMA nano-antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used.
- Trial name
- BCMA CAR-T (NCT03661554)
- Testing
- BCMA CAR-T Cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Pregene (ShenZhen) Biotechnology Company, Ltd.
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Periodontitis
Effect of Tooth Cleaning in Smokers and Non Smokers With Gum Disease.
This study is intended to measure hepatocyte growth factor levels in smokers and non smokers with periodontitis before and after non surgical periodontal therapy.
- Trial name
- ETCSNSGD (NCT02930356)
- Testing
- NSPT, Scaling and root planing
- Volunteers
- 40 people
- Sponsor
- Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
Multiple Myeloma
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
This is an open Label, Phase I/II, multicenter study. In the first phase it defines the maximum tolerated dose (MTD) of Bendamustine (B) given in combination with Lenalidomide (L) and low-dose Dexamethasone (d) and in the second…
- Trial name
- NCT01686386
- Testing
- Bendamustine, Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Studio Linfomi
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
study evaluates a biomarker-guided strategy to assign adults with refractory SLE to autologous CAR-T therapy targeting either CD19 or BCMA.
- Trial name
- SELECT-SLE (NCT07523542)
- Testing
- Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.